| UniProt/SwissProt ID: | ENOA_HUMAN |
| Description: | enolase 1, (alpha) [Source:HGNC Symbol;Acc:3350] |
| Location: | chr1 p36.23 |
| Node attribute: | substrate; TF |
| Phosphorylation site |
| Position | PhosphoPeptide | Catalytic kinase | Source |
|---|---|---|---|
| S419 | EEELGsKAKFA | HPRD | |
| S27 | VDLFTsKGLFR | HPRD | |
| Y287 | SFIKDyPVVSI | Enolase_C | PhosphoSitePlus |
| Y44 | ASTGIyEALEL | SRC | phosphoELM; SysPTM |
| T100 | IEMDGtENKSK | HPRD | |
| Y236 | IGKAGyTDKVV | Enolase_C | PhosphoSitePlus |
| Y280 | QLADLyKSFIK | Enolase_C | PhosphoSitePlus |
| T26 | EVDLFtSKGLF | Enolase_N | PhosphoSitePlus |
| T41 | PSGAStGIYEA | Enolase_N | PhosphoSitePlus |
| T390 | VVGLCtGQIKT | Enolase_C | PhosphoSitePlus |
| S37 | RAAVPsGASTG | Enolase_N | PhosphoSitePlus |
| S282 | ADLYKsFIKDY | Enolase_C | PhosphoSitePlus |
| S263 | DLDFKsPDDPS | Enolase_C | PhosphoSitePlus; SysPTM |
| S370 | WGVMVsHRSGE | Enolase_C | PhosphoSitePlus |
| Y257 | FRSGKyDLDFK | Enolase_C | PhosphoSitePlus |
| T100 | IEMDGtENKSK | Enolase_N | PhosphoSitePlus |
| T237 | GKAGYtDKVVI | Enolase_C | PhosphoSitePlus |
| S419 | EEELGsKAKFA | Enolase_C | PhosphoSitePlus |
| S40 | VPSGAsTGIYE | Enolase_N | PhosphoSitePlus |
| Y44 | ASTGIyEALEL | Src | RegPhos; SysPTM |
| Y287 | SFIKDyPVVSI | HPRD; phosphoELM; RegPhos | |
| S14 | REIFDsRGNPT | Enolase_N | PhosphoSitePlus |
| S254 | SEFFRsGKYDL | HPRD; SysPTM | |
| Y44 | ASTGIyEALEL | Enolase_N | PhosphoSitePlus; SysPTM |
| S263 | DLDFKsPDDPS | HPRD; RegPhos; SysPTM | |
| S63 | MGKGVsKAVEH | phosphoELM; RegPhos | |
| Y44 | ASTGIyEALEL | HPRD; phosphoELM; RegPhos; SysPTM | |
| S272 | PSRYIsPDQLA | Enolase_C | PhosphoSitePlus |
| T55 | RDNDKtRYMGK | Enolase_N | PhosphoSitePlus |
| S291 | DYPVVsIEDPF | Enolase_C | PhosphoSitePlus |
| S254 | SEFFRsGKYDL | Enolase_C | PhosphoSitePlus; SysPTM |
| Y57 | NDKTRyMGKGV | Enolase_N | PhosphoSitePlus; SysPTM |
| Y57 | NDKTRyMGKGV | HPRD; phosphoELM; RegPhos; SysPTM | |
| T72 | EHINKtIAPAL | HPRD; RegPhos | |
| S79 | APALVsKKLNV | Enolase_N | PhosphoSitePlus |
| S27 | VDLFTsKGLFR | Enolase_N | PhosphoSitePlus |
| Y131 | KGVPLyRHIAD | Enolase_N | PhosphoSitePlus |
| S336 | AVNEKsCNCLL | Enolase_C | PhosphoSitePlus |
| Y189 | IGAEVyHNLKN | Enolase_C | PhosphoSitePlus |
| Dephosphorylation site |
| ENOA_HUMAN do not have dephosphorylation site. |
| Mutation site |
| Ensembl ID | Variation | Source | Cancer name | Pubmed |
|---|---|---|---|---|
| ENSP00000234590 | V147M | BIOMART | Neoplasms by Histologic Type | 21930507, 21930502 | ENSP00000234590 | V240M | COSMIC | Central Nervous System Neoplasms | 18772396 | ENSP00000234590 | G212R | COSMIC | Head and Neck Cancer | 21798893 |
| Differential expressed protein |
| Ensembl ID | Cancer name | Design | Sample | Change | Ratio | Pubmed |
|---|---|---|---|---|---|---|
| ENSP00000234590 | Non-small cell lung carcinoma | Metastasis | cell line | Up | 17537172 | ENSP00000234590 | Pancreatic Cancer | Normal vs. Cancer | tissue | Down | 0.2 | 16215274 | ENSP00000234590 | colorectal cancer | Normal vs. Cancer | tissue | Up | 2.4 | 16554294 | ENSP00000234590 | Hepatocellular Carcinoma | Normal vs. Cancer | tissue | Up | 2.8 | 15759316 | ENSP00000234590 | Breast Cancer | Metastasis | cell line | Up | 7 | 16048908 | ENSP00000234590 | Leukemia | Normal vs. Cancer | cell line | Down | 0.29 | 17022645 | ENSP00000234590 | Leukemia | Normal vs. Cancer | cell line | Down | 0.43 | 17022645 | ENSP00000234590 | Breast Cancer | Treatment (chemosensitive vs. adriamycin-resistant) | cell line | Up | 3 | 17487377 | ENSP00000234590 | Breast Cancer | Metastasis | cell line | Up | 17608509 | ENSP00000234590 | Melanoma | Treatment (none vs. metastasis suppressor 1 (BRMS1) overEXPressed) | cell line | Down | 0.46 | 17854218 | ENSP00000234590 | Melanoma | Treatment (none vs. metastasis suppressor 1 (BRMS1) silenced) | cell line | Up | 1.8 | 17854218 | ENSP00000234590 | Neoplasms by Histologic Type | Normal vs. Cancer | tissue | Down | 0.73 | 18259946 | ENSP00000234590 | breast ductal carcinoma | Normal vs. Cancer | tissue | Up | 11 | 18401453 | ENSP00000234590 | hepatitis B virus | Normal vs. Cancer | tissue | Down | 0.67 | 14654528 | ENSP00000234590 | Hepatocellular Carcinoma | Normal vs. Cancer | tissue | Up | 2 | 14654528 | ENSP00000234590 | hepatitis B virus | Normal vs. Cancer | cell line | Up | 5.3 | 19187611 | ENSP00000234590 | hepatitis B virus | Treatment (none vs tetracycline-treatment) | cell line | Down | 0.48 | 19671925 | ENSP00000234590 | Hepatocellular Carcinoma | Cancer vs. Cancer (HCC vs. HuCCA) | cell line | Up | 20069059 | ENSP00000234590 | Colorectal Cancer | Treatment (none vs transfected with HPV-16 E6 gene) | cell line | Down | 15684709 | ENSP00000234590 | Lung Cancer | Normal vs. Cancer | tissue | Down | 16342241 | ENSP00000234590 | Lung Cancer | Cancer vs. Cancer | cell line | Down | 17284061 | ENSP00000234590 | Gastric Cancer | Normal vs. Cancer | tissue | Up | 12 | 18723843 | ENSP00000234590 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.39 | 20052998 | ENSP00000234590 | Breast Cancer | Normal vs. Cancer | cell line | Up | 1.9 | 20052998 | ENSP00000234590 | Breast Cancer | Metastasis | cell line | Up | 4.9 | 20052998 | ENSP00000234590 | Breast Cancer | Normal vs. Cancer | cell line | Up | 1.3 | 20052998 | ENSP00000234590 | Breast Cancer | Normal vs. Cancer | cell line | Up | 1.6 | 20052998 | ENSP00000234590 | Breast Cancer | Metastasis | cell line | Up | 1.2 | 20052998 | ENSP00000234590 | Breast Cancer | Cancer vs. Cancer (Non-TNBC vs. TNBC) | cell line | Up | 20596302 | ENSP00000234590 | Breast Cancer | Cancer vs. Cancer (Non-TNBC vs. TNBC) | cell line | Up | 20596302 | ENSP00000234590 | breast ductal carcinoma | Normal vs. Cancer | tissue | Up | 18564057 | ENSP00000234590 | Oral Cancer | Normal vs. Cancer | tissue | Up | 4.3 | 19691830 | ENSP00000234590 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Up | 2.9 | 17655343 | ENSP00000234590 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Up | 5.7 | 17655343 | ENSP00000234590 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Up | 12 | 17655343 | ENSP00000234590 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Up | 17655343 | ENSP00000234590 | Renal Cancer | Normal vs. Cancer | tissue | Up | 1.8-4.5 | 12923786 | ENSP00000234590 | Renal Cancer | Normal vs. Cancer | tissue | Up | 19164279 | ENSP00000234590 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.77 | 18973835 | ENSP00000234590 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.83 | 18973835 | ENSP00000234590 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.53 | 18973835 | ENSP00000234590 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.56 | 18973835 | ENSP00000234590 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.77 | 19714814 | ENSP00000234590 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.83 | 19714814 | ENSP00000234590 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Up | 2 | 19714814 | ENSP00000234590 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.023 | 20858016 | ENSP00000234590 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.026 | 20858016 | ENSP00000234590 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Down | 0.4 | 20858016 | ENSP00000234590 | Pancreatic Cancer | Normal vs. Cancer | tissue | Up | 2 | 15526344 | ENSP00000234590 | Esophageal Cancer | Normal vs. Cancer | tissue | Up | 2.4 | 16400690 | ENSP00000234590 | Esophageal Cancer | Normal vs. Cancer | cell line | Down | 0.31 | 19090015 | ENSP00000234590 | Esophageal Cancer | Normal vs. Cancer | cell line | Down | 0.32 | 19090015 | ENSP00000234590 | Uterine Cancer | Treatment(none vs. transfected with the pOP13 vector that containing E7) | cell line | Up | 14997504 | ENSP00000234590 | Gastric Cancer | Normal vs. Cancer | tissue | Down | 0.5 | 15761955 | ENSP00000234590 | Uterine Cancer | Normal vs. Cancer | tissue | Down | 16051329 | ENSP00000234590 | Uterine Cancer | Cancer vs. Cancer | cell line | Down | 17616526 | ENSP00000234590 | Uterine Cancer | Treatment(21% oxygen vs. 1% oxygen (mild hypoxia) supplemented ) | cell line | Up | 19541378 | ENSP00000234590 | Uterine Cancer | Treatment(21% oxygen vs. 0% oxygen (mild hypoxia) supplemented ) | cell line | Up | 19541378 | ENSP00000234590 | Head and Neck Cancer | Treatment(21% oxygen vs. 1% oxygen (mild hypoxia) supplemented ) | cell line | Up | 19541378 | ENSP00000234590 | Head and Neck Cancer | Treatment(21% oxygen vs 0% oxygen (mild hypoxia) supplemented ) | cell line | Up | 19541378 | ENSP00000234590 | Uterine Cancer | Normal vs. Cancer | tissue | Down | 19771267 | ENSP00000234590 | pancreatic ductal adenocarcinoma | Normal vs. Cancer | tissue | Up | 17492507 | ENSP00000234590 | Pancreatic Cancer | Normal vs. Cancer | tissue | Up | 2.5 | 19199705 |
| Hyperphosphorylation site |
| Site | Motif | Peptide | Cancer name | Pubmed | Source |
|---|---|---|---|---|---|
| S419 | Enolase_C | RIEEELGsKAKFAGR | pancreatic carcinoma | 20455595 | PhosphoSitePlus |
| Direct Interaction Pair |
| Source | Target | Relationship | Resource |
|---|---|---|---|
| ZAGL2_HUMAN | ENOA_HUMAN | kinase -> substrate | RegPhos |
| WEE1_HUMAN | ENOA_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| YES_HUMAN | ENOA_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| FGR_HUMAN | ENOA_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| KPCI_HUMAN | ENOA_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| ST17A_HUMAN | ENOA_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| KS6A4_HUMAN | ENOA_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| GRK5_HUMAN | ENOA_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| ENOA_HUMAN | MYC_HUMAN | TF -> target gene | TRANSFAC |
| Function Annotation |
| KEGG Pathway |
| KEGG ID | Pathway |
|---|---|
| hsa00010 | Glycolysis / Gluconeogenesis |
| hsa03018 | RNA degradation |
| hsa01100 | Metabolic pathways |
| Gene Ontology |
| GO ID | GO_Term | Evidence | Ontology |
|---|---|---|---|
| GO:0000015 | phosphopyruvate hydratase complex | IEA | cellular_component |
| GO:0005975 | carbohydrate metabolic process | TAS | biological_process |
| GO:0003700 | sequence-specific DNA binding transcription factor | TAS | molecular_function |
| GO:0004634 | phosphopyruvate hydratase activity | IEA | molecular_function |
| GO:0005829 | cytosol | TAS | cellular_component |
| GO:0044281 | small molecule metabolic process | TAS | biological_process |
| GO:0070062 | extracellular vesicular exosome | IDA | cellular_component |
| GO:0005515 | protein binding | IPI | molecular_function |
| GO:0006351 | transcription, DNA-dependent | IEA | biological_process |
| GO:0000287 | magnesium ion binding | IEA | molecular_function |
| GO:0003677 | DNA binding | IEA | molecular_function |
| GO:0006006 | glucose metabolic process | TAS | biological_process |
| GO:0005886 | plasma membrane | IEA | cellular_component |
| GO:0031430 | M band | IEA | cellular_component |
| GO:0005737 | cytoplasm | IDA | cellular_component |
| GO:0006094 | gluconeogenesis | TAS | biological_process |
| GO:0005634 | nucleus | IC | cellular_component |
| GO:0030308 | negative regulation of cell growth | IDA | biological_process |
| GO:0009615 | response to virus | IEP | biological_process |
| GO:0003714 | transcription corepressor activity | TAS | molecular_function |
| GO:0006096 | glycolysis | IEA | biological_process |
| GO:0045892 | negative regulation of transcription, DNA-dependen | IDA | biological_process |
| GO:0000122 | negative regulation of transcription from RNA poly | TAS | biological_process |